Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update

作者：Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, R. Bryan Rumble, Mary‐Ellen Taplin, Terry M. Kungel, Daniel Herchenhorn, Tian Zhang, Kathryn E. Beckermann, Neha Vapiwala, Michael A. Carducci, Paul Celano, Sebastién J. Hotte, Arnab Basu, Hala T. Borno, Alan H. Bryce, Peng Wang, Elizabeth Wulff‐Burchfield, Lisa Bodei, Andrew Loblaw, Robert J. Hamilton, Hamid Emamekhoo, Thomas A. Hope, Huan He, M. Hassan Murad, Hongfang Liu, J.E. Caerwyn Williams, Rahul Atul Parikh · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco-25-00007 · 被引用次数：50 · 研究领域：Prostate Cancer Treatment and Research、PARP inhibition in cancer therapy、Radiopharmaceutical Chemistry and Applications

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemother...